Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Humanwell Healthcare (group) Co., Ltd.

Medshine Discovery Inc.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Guizhou Inochini Technology Co., Ltd

Humanwell Healthcare Co., Ltd.

Cailin Wang

Shuhui Chen

Jian Li

Yong Wang

Lingyun Wu

Yong Xu

Lie Li

Lu Huang

Xuehai Wang

Ronghua Tu

Hailiang Chen

Wenjie Sun

Charles Z Ding

Zheng Wang

Cong Wang

Hui Liu

Weidong Li

Jie Shen

Yang YuE

Biao Deng

Jimeng Wang

Peng Zhang

Yi Chen

Jun Yin

Zhaozhong Ding

Lele Zhao

Wen Jiang

Zhaoguo Chen

Zhibo Zhang

Xiongbin Xu

Xiawei Wei

Yang Yue

XiaWei Wei

Zheming Xiao

Ru Feng

Gang Li

Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.

Compound as porcupine inhibitor and use thereof

The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof. 

Benzopyrazole compound used as RHO kinase inhibitor

Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.

Dimethylphosphine oxide compound

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound has the structure of Compound 2. 

Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1,5-alpha]benzimidazole compound and a preparation method and intermediate thereof. The 4H-pyrazolo[1,5-alpha]benzimidazole compound is represented by formula I: 

Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof

Disclosed is a series of analogs of 4H-pyrazolo[1,5-&#x3b1;]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors

Growing community of inventors

Shanghai, China

Cailin Wang